229 related articles for article (PubMed ID: 33945142)
21. Human Leukocyte Antigen Class I Pseudo-Homozygous Mesenchymal Stem Cells Derived from Human Induced Pluripotent Stem Cells.
Kwon D; Ahn HJ; Han MJ; Ji M; Ahn J; Seo KW; Kang KS
Stem Cell Rev Rep; 2020 Aug; 16(4):792-808. PubMed ID: 32712868
[TBL] [Abstract][Full Text] [Related]
22. Fluorescent labeling of CRISPR/Cas9 RNP for gene knockout in HSPCs and iPSCs reveals an essential role for GADD45b in stress response.
Nasri M; Mir P; Dannenmann B; Amend D; Skroblyn T; Xu Y; Schulze-Osthoff K; Klimiankou M; Welte K; Skokowa J
Blood Adv; 2019 Jan; 3(1):63-71. PubMed ID: 30622144
[TBL] [Abstract][Full Text] [Related]
23. CRISPR/Cas9-Mediated Genome Editing to Generate Clonal iPSC Lines.
Sanjurjo-Soriano C; Erkilic N; Mamaeva D; Kalatzis V
Methods Mol Biol; 2022; 2454():589-606. PubMed ID: 33755901
[TBL] [Abstract][Full Text] [Related]
24. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
[TBL] [Abstract][Full Text] [Related]
25. Generation and characterization of HLA-universal platelets derived from induced pluripotent stem cells.
Norbnop P; Ingrungruanglert P; Israsena N; Suphapeetiporn K; Shotelersuk V
Sci Rep; 2020 May; 10(1):8472. PubMed ID: 32439978
[TBL] [Abstract][Full Text] [Related]
26. Efficient Gene Editing of Human Induced Pluripotent Stem Cells Using CRISPR/Cas9.
Yumlu S; Bashir S; Stumm J; Kühn R
Methods Mol Biol; 2019; 1961():137-151. PubMed ID: 30912045
[TBL] [Abstract][Full Text] [Related]
27. Diminished expression of major histocompatibility complex facilitates the use of human induced pluripotent stem cells in monkey.
Wang X; Lu M; Tian X; Ren Y; Li Y; Xiang M; Chen S
Stem Cell Res Ther; 2020 Aug; 11(1):334. PubMed ID: 32746912
[TBL] [Abstract][Full Text] [Related]
28. Efficient Generation and Editing of Feeder-free IPSCs from Human Pancreatic Cells Using the CRISPR-Cas9 System.
Nandal A; Mallon B; Telugu BP
J Vis Exp; 2017 Nov; (129):. PubMed ID: 29155789
[TBL] [Abstract][Full Text] [Related]
29. Knockout of beta-2 microglobulin enhances cardiac repair by modulating exosome imprinting and inhibiting stem cell-induced immune rejection.
Shao L; Zhang Y; Pan X; Liu B; Liang C; Zhang Y; Wang Y; Yan B; Xie W; Sun Y; Shen Z; Yu XY; Li Y
Cell Mol Life Sci; 2020 Mar; 77(5):937-952. PubMed ID: 31312880
[TBL] [Abstract][Full Text] [Related]
30. HDAC inhibitors improve CRISPR-mediated HDR editing efficiency in iPSCs.
Zhang JP; Yang ZX; Zhang F; Fu YW; Dai XY; Wen W; Zhang B; Choi H; Chen W; Brown M; Baylink D; Zhang L; Qiu H; Wang C; Cheng T; Zhang XB
Sci China Life Sci; 2021 Sep; 64(9):1449-1462. PubMed ID: 33420926
[TBL] [Abstract][Full Text] [Related]
31. Abrogation of HLA surface expression using CRISPR/Cas9 genome editing: a step toward universal T cell therapy.
Lee J; Sheen JH; Lim O; Lee Y; Ryu J; Shin D; Kim YY; Kim M
Sci Rep; 2020 Oct; 10(1):17753. PubMed ID: 33082438
[TBL] [Abstract][Full Text] [Related]
32. Generation of a B2M homozygous knockout human somatic cell nuclear transfer-derived embryonic stem cell line using the CRISPR/Cas9 system.
Lee OH; Lee S; Park M; Moon S; Hwang S; Kim B; Kim CY; Lee DR; Shim SH; Park KH; Chung HM; Choi Y
Stem Cell Res; 2022 Mar; 59():102643. PubMed ID: 34971932
[TBL] [Abstract][Full Text] [Related]
33. Generation of universal and hypoimmunogenic human pluripotent stem cells.
Ye Q; Sung TC; Yang JM; Ling QD; He Y; Higuchi A
Cell Prolif; 2020 Dec; 53(12):e12946. PubMed ID: 33174655
[TBL] [Abstract][Full Text] [Related]
34. One-step genetic correction of hemoglobin E/beta-thalassemia patient-derived iPSCs by the CRISPR/Cas9 system.
Wattanapanitch M; Damkham N; Potirat P; Trakarnsanga K; Janan M; U-Pratya Y; Kheolamai P; Klincumhom N; Issaragrisil S
Stem Cell Res Ther; 2018 Feb; 9(1):46. PubMed ID: 29482624
[TBL] [Abstract][Full Text] [Related]
35. Universal and hypoimmunogenic pluripotent stem cells for clinical usage.
Sung TC; Maitiruze K; Pan J; Gong J; Bai Y; Pan X; Higuchi A
Prog Mol Biol Transl Sci; 2023; 199():271-296. PubMed ID: 37678974
[TBL] [Abstract][Full Text] [Related]
36. Universal cell donor lines: A review of the current research.
Simpson A; Hewitt AW; Fairfax KA
Stem Cell Reports; 2023 Nov; 18(11):2038-2046. PubMed ID: 37832541
[TBL] [Abstract][Full Text] [Related]
37. Current status and future perspectives of HLA-edited induced pluripotent stem cells.
Koga K; Wang B; Kaneko S
Inflamm Regen; 2020; 40():23. PubMed ID: 33014207
[TBL] [Abstract][Full Text] [Related]
38. Generation of NPHP1 knockout human pluripotent stem cells by a practical biallelic gene deletion strategy using CRISPR/Cas9 and ssODN.
Nakano Y; Susa K; Yanagi T; Hiraoka Y; Suzuki T; Mori T; Ando F; Mandai S; Fujiki T; Rai T; Uchida S; Sohara E
In Vitro Cell Dev Biol Anim; 2022 Feb; 58(2):85-95. PubMed ID: 35165826
[TBL] [Abstract][Full Text] [Related]
39. Universal Correction of Blood Coagulation Factor VIII in Patient-Derived Induced Pluripotent Stem Cells Using CRISPR/Cas9.
Park CY; Sung JJ; Cho SR; Kim J; Kim DW
Stem Cell Reports; 2019 Jun; 12(6):1242-1249. PubMed ID: 31105049
[TBL] [Abstract][Full Text] [Related]
40. CRISPR-Cas9-Based Genome Editing of Human Induced Pluripotent Stem Cells.
Giacalone JC; Sharma TP; Burnight ER; Fingert JF; Mullins RF; Stone EM; Tucker BA
Curr Protoc Stem Cell Biol; 2018 Feb; 44():5B.7.1-5B.7.22. PubMed ID: 29512106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
